Creso Pharma to benefit from OTC cannabis sales in Australia
Creso Pharma Limited (ASX:CPH, FRA: 1X8) is one of several cannabis stocks to respond positively today to what is considered to be a major announcement by the Therapeutic Goods Administration (TGA).
The TGA has announced its interim decision in relation to a major regulatory change in the status of cannabidiol (CBD) products in Australia.
This decision recommends that CBD products be down-scheduled from schedule 4 and classified as schedule 3 medicines in Australia.
This would allow Australian consumers to purchase CBD products over-the-counter (OTC) through pharmacies without the requirement of a prescription.
The decision follows recommendations from the National Advisory Committee on Medicines Scheduling (ACMS) and Advisory Committee on Chemicals Scheduling (ACCS), with both committees being within Australia’s Therapeutic Goods Administration (TGA).
The interim decision will follow a consultation period with a final decision to be reached by 1 February, 2021.
Creso Pharma targeting a $200 million market in Australia
This development unlocks a major opportunity for Creso Pharma CBD and hemp products, and management will look to progress a number of opportunities to capitalise on a market which is estimated to be valued at $200 million and set to grow rapidly in the near term.
Currently, Creso Pharma’s cannaQIX® 50 is being sold in Australia as a medicinal cannabis product under the ‘LozaCan’ brand via distribution partner Burleighs Heads Cannabis’ (BHC).
Creso Pharma has developed various cannabidiol (CBD) hemp oil-based products in their cannaQIX® range using the company’s proprietary innovative delivery technology.
The products contain broad spectrum organic hemp oil extracts with CBD and they are pitched at reducing stress and supporting mental and nervous functions.
Commenting on Creso Pharma’s extensive product range of opportunities that are now on offer in the Australian market, non-executive chairman Adam Blumenthal said, "The down scheduling of CBD products in Australia is an exciting development and provides Creso Pharma with a number of key near term opportunities.
“We anticipate that the Australian market will play an important role in the company’s growth trajectory and will grow significantly as CBD becomes more accepted and entrenched with consumers.
“Creso Pharma has a large GMP product range and we are confident that the company’s offering will be well received in Australia.
‘’Board and management are currently progressing a number of strategies to grow our market share and we look forward to providing regular updates to shareholders.”
Creso Pharma products have competitive edge
The cannaQIX® range of products has several features that set them aside from other competing products, being sugar-free and containing no tetrahydrocannabinol (THC).
The standardised, user-friendly strength and formulation allows precise dosage control and the lozenges have a more palatable taste compared to oils.
The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso Pharma’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG.
The presence of a ‘’Swiss Made’’ label emphasises the premium quality control measures that define Creso Pharma’s products.
Like this article? You may like...
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
